Bristol-Myers Squibb (US) invests in gene sequencing:
This article was originally published in Clinica
Bristol-Myers Squibb (US) is providing funding for the continued development of SEQ's (US) proprietary gene sequencing technology. In connection with the investment, BMS will obtain access to gene sequencing services on preferential terms. Leon Rosenberg, president of BMS Pharmaceutical Research Institute, has joined SEQ's board.